Tech Company Financing Transactions
Cleave Biosciences Funding Round
5AM Ventures, Arcus Ventures and Astellas Venture Capital participated in a $37 million Series B venture round for Cleave Biosciences. The round closed on 8/9/2016.
Transaction Overview
Company Name
Announced On
8/9/2016
Transaction Type
Venture Equity
Amount
$37,000,000
Round
Series B
Investors
Proceeds Purpose
The funds will be used to support further clinical development of CB-5083, the company's lead oncology drug candidate, and discovery efforts related to the company's AAA ATPase platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
863 Mitten Rd. 104
Burlingame, CA 94010
USA
Burlingame, CA 94010
USA
Phone
Website
Email Address
Overview
Cleave Biosciences is focused on targets in cellular protein homeostasis pathways controlled by the ubiquitin proteasome and the autophagy systems, which are utilized by cancer cells in their growth and survival.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amy Burroughs
VP - Finance
Tanya Bowman
VP - Operations
Sujatha Venugopal-Prasad
VP - Regulatory Affairs
Kerry Kelly
Browse more venture capital transactions:
Prev: 8/9/2016: HashRabbit venture capital transaction
Next: 8/10/2016: Emotech venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs